Medigen Biotechnology Corp. (TPEX:3176)

Market Cap	4.56B +12.0%
Revenue (ttm)	1.34B -17.0%
Net Income	-264.40M
EPS	-1.89
Shares Out	139.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	718,074
Open	33.40
Previous Close	33.10
Day's Range	32.70 - 33.60
52-Week Range	28.00 - 43.60
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2025, Medigen Biotechnology's revenue was 1.58 billion, an increase of 15.28% compared to the previous year's 1.37 billion. Losses were -108.80 million, -46.84% less than in 2024.